- Nanoform has signed an exclusivity agreement with a Nasdaq-listed U.S. biopharmaceutical company for use of its biologics nanoparticle technology in subcutaneous biologic medicines.
- The agreement includes an initial $1 million payment, potential milestone payments worth up to high tens of millions of dollars, and future royalties tied to commercialization.
Nanoform has entered into an exclusivity agreement with a U.S.-based biopharmaceutical company for the application of its biologics nanoparticle technology in the development of subcutaneous biologic medicines.
Under the agreement, the partner company will pay Nanoform a non-refundable $1 million fee for one year of exclusivity covering one clinically and commercially validated therapeutic target receptor. The agreement also includes an option to extend exclusivity for an additional year through another $1 million payment. Nanoform stated that future milestone payments could reach high tens of millions of dollars, alongside royalties and potential service and supply revenues linked to product commercialization.
According to Nanoform, its biologics manufacturing technology enables biologic compounds, including peptides and monoclonal antibodies, to be converted into stable nanoparticles that support higher-concentration formulations. The company said the platform can enable biologic suspensions exceeding 500 mg/mL, potentially reducing injection volumes and supporting subcutaneous or inhaled delivery of therapies traditionally administered intravenously.
“We are excited by the advanced pre-clinical data our partner has generated with our biologics technology. This is our first exclusivity agreement for the biologics technology for a therapeutic target.”
Prof. Edward Hæggström, Chief Executive Officer of Nanoform
Nanoform stated that the agreement remains contingent on continued progress toward establishing GMP-grade clinical supply and the partner’s continued clinical and commercial development activities. The company added that it continues to engage with pharmaceutical and biotechnology companies on applications of its nanoparticle technologies across biologics and small molecule programs.
